Vedroprevir
Vedroprevir (GS-9451) is an inhibitor for HCV NS3/4A protease with an IC50 of 3.2 nM. Vedroprevir is also an inhibitor for breast cancer resistant protein (BCRP) with an IC50 of 1.4 μM. Vedroprevir inhibits P-gp, MRP1 and MRP2 with IC50 of 34, 14.9 and 12 μM, respectively. Vedroprevir exhibits good pharmacokinetic characteristics in rats and dogs.
For research use only. We do not sell to patients.
- CAS No.: 1098189-15-1
- Formula: C45H60ClN7O9S
- Molecular Weight:910.52
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-10241
SimeprevirHCV NS3/4A Inhibitor -
HY-12530
VelpatasvirHCV NS5A Inhibitor -
HY-13998
DasabuvirHCV Polymerase Inhibitor -
HY-10443
BalapiravirAnti-HCV Agent -
HY-13997
OmbitasvirHCV NS5A Inhibitor -
HY-100008
PeretinoinAcyclic Retinoid -
HY-10444
R-1479RdRp Inhibitor -
HY-12530R
Velpatasvir (Standard)HCV NS5A Inhibitor -
HY-109035
Inarigivir soproxilHCV/HBV Inhibitor -
HY-124806
TTP-8307HCV Inhibitor -
HY-109571
HZ-1157HCV NS3/4A Inhibitor -
HY-13997R
Ombitasvir (Standard)HCV NS5A Inhibitor
Biological Activity
Description
IC50 & Target
IC50: 3.2 nM (HCV NS3/4A protease), 1.4 μM (BCRP), 34 μM (P-gp), 14.9 μM (MRP1), 12 μM (MRP2)
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1098189-15-1
-
Molecular Weight 910.52
-
Formula C45H60ClN7O9S
-
SMILES
O=C([C@H]1N(C[C@@H](C1)OC2=CC(C3=CSC(NC(C)C)=N3)=NC4=C2C=CC(OCCN5CCOCC5)=C4Cl)C([C@H](C(C)(C)C)NC(O[C@H]6C[C@]7([H])[C@](C7)([H])C6)=O)=O)N[C@]8([C@@H](C8)CC)C(O)=O
-
Synonyms
GS-9451
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Vedroprevir Related Classifications
HY-16773 Related Classifications
Powered by Bioz